AFT welcomes Australian Federal Court appeal success

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





9 December 2021

AFT welcomes Australian Federal Court appeal success
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today welcomes the Australian Federal
Court’s decision this week to allow its appeal of a comparative advertising judgement
brought by Reckitt Benckiser.
The Australian Federal Court has found AFT was justified in making a series of claims in
relation to the efficacy of its Maxigesic pain relief tablets in comparison to Ibuprofen
alone or paracetamol alone.
Reckitt Benckiser has until 4 January 2022 to file an application for special leave to
appeal to the High Court should it so chose.
We are therefore unable to make further comment at this time.

For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over the counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to over 125 countries around the world. For more
information about the company, visit our website www.aftpharm.com
.